| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Department of Anesthesiology,*
Ajou University
School of Medicine, Suwon, Korea; the Department of
Pharmacology,
University of Pittsburgh,
Pittsburgh, Pennsylvania; the Department of
Surgery,
The University of Texas Health
Science Center at San Antonio, San Antonio, Texas; and the Department
of Pathology,
Wayne State University School of
Medicine and Karmanos Cancer Institute, Detroit, Michigan
Galectin-3 is a ß-galactoside-binding protein which regulates many biological processes including cell adhesion, migration, cell growth, tumor progression, metastasis, and apoptosis. Although the exact function of galectin-3 in cancer development is unclear, galectin-3 expression is associated with neoplastic progression and metastatic potential. Since studies have suggested that tumor cell survival in microcirculation determines the metastatic outcome, we examined the effect of galectin-3 overexpression in human breast carcinoma cell survival using the liver ischemia/reperfusion metastasis model. While the majority of control cells died by hepatic ischemia/reoxygenation, nearly all of galectin-3 overexpressing cells survived. We showed that galectin-3 inhibits nitrogen free radical-mediated apoptosis, one of the major death pathways induced during hepatic ischemia/reperfusion. Galectin-3 inhibition of apoptosis involved protection of mitochondrial integrity, inhibition of cytochrome c release and caspase activation. Taking these results together with the previous observation that galectin-3 inhibits apoptosis induced by loss of cell adhesion, we propose that galectin-3 is a critical determinant for anchorage-independent and free radical-resistant cell survival during metastasis.
This article has been cited by other articles:
 |
|
 |
|
  T. Szoke, K. Kayser, I. Trojan, G. Kayser, J. Furak, L. Tiszlavicz, J.-D. Baumhakel, and H.-J. Gabius The role of microvascularization and growth/adhesion-regulatory lectins in the prognosis of non-small cell lung cancer in stage II Eur. J. Cardiothorac. Surg., May 1, 2007; 31(5): 783 - 787. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. G. Prieto, A. A. Mourad-Zeidan, V. Melnikova, M. M. Johnson, A. Lopez, A. H. Diwan, A. J.F. Lazar, S. S. Shen, P. S. Zhang, J. A. Reed, et al. Galectin-3 Expression Is Associated with Tumor Progression and Pattern of Sun Exposure in Melanoma. Clin. Cancer Res., November 15, 2006; 12(22): 6709 - 6715. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. N. Stillman, D. K. Hsu, M. Pang, C. F. Brewer, P. Johnson, F.-T. Liu, and L. G. Baum Galectin-3 and Galectin-1 Bind Distinct Cell Surface Glycoprotein Receptors to Induce T Cell Death J. Immunol., January 15, 2006; 176(2): 778 - 789. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Mazurek, Y. J. Sun, J. E. Price, L. Ramdas, W. Schober, P. Nangia-Makker, J. C. Byrd, A. Raz, and R. S. Bresalier Phosphorylation of Galectin-3 Contributes to Malignant Transformation of Human Epithelial Cells via Modulation of Unique Sets of Genes Cancer Res., December 1, 2005; 65(23): 10767 - 10775. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. C. Fernandez, J. M. Ilarregui, C. J. Rubel, M. A. Toscano, S. A. Gomez, M. Beigier Bompadre, M. A. Isturiz, G. A. Rabinovich, and M. S. Palermo Galectin-3 and soluble fibrinogen act in concert to modulate neutrophil activation and survival: involvement of alternative MAPK pathways Glycobiology, May 1, 2005; 15(5): 519 - 527. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. B. Wreesmann, E. M. Sieczka, N. D. Socci, M. Hezel, T. J. Belbin, G. Childs, S. G. Patel, K. N. Patel, G. Tallini, M. Prystowsky, et al. Genome-Wide Profiling of Papillary Thyroid Cancer Identifies MUC1 as an Independent Prognostic Marker Cancer Res., June 1, 2004; 64(11): 3780 - 3789. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Takenaka, T. Fukumori, T. Yoshii, N. Oka, H. Inohara, H.-R. C. Kim, R. S. Bresalier, and A. Raz Nuclear Export of Phosphorylated Galectin-3 Regulates Its Antiapoptotic Activity in Response to Chemotherapeutic Drugs Mol. Cell. Biol., May 15, 2004; 24(10): 4395 - 4406. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Hoyer, M. Pang, D. Gui, I. P. Shintaku, I. Kuwabara, F.-T. Liu, J. W. Said, L. G. Baum, and M. A. Teitell An Anti-Apoptotic Role for Galectin-3 in Diffuse Large B-Cell Lymphomas Am. J. Pathol., March 1, 2004; 164(3): 893 - 902. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. John, H. Leffler, B. Kahl-Knutsson, I. Svensson, and G. A. Jarvis Truncated Galectin-3 Inhibits Tumor Growth and Metastasis in Orthotopic Nude Mouse Model of Human Breast Cancer Clin. Cancer Res., June 1, 2003; 9(6): 2374 - 2383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Qiu, F.W. Orr, D. Jensen, H. H. Wang, A. R. McIntosh, B. B. Hasinoff, D. M. Nance, S. Pylypas, K. Qi, C. Song, et al. Arrest of B16 Melanoma Cells in the Mouse Pulmonary Microcirculation Induces Endothelial Nitric Oxide Synthase-Dependent Nitric Oxide Release that Is Cytotoxic to the Tumor Cells Am. J. Pathol., February 1, 2003; 162(2): 403 - 412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Hernandez and L. G. Baum Ah, sweet mystery of death! Galectins and control of cell fate Glycobiology, October 1, 2002; 12(10): 127R - 136R. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Rabinovich, N. Rubinstein, and L. Fainboim Unlocking the secrets of galectins: a challenge at the frontier of glyco-immunology J. Leukoc. Biol., May 1, 2002; 71(5): 741 - 752. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Yoshii, T. Fukumori, Y. Honjo, H. Inohara, H.-R. C. Kim, and A. Raz Galectin-3 Phosphorylation Is Required for Its Anti-apoptotic Function and Cell Cycle Arrest J. Biol. Chem., February 22, 2002; 277(9): 6852 - 6857. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. J. Lee and Y. K. Song Cooperative Interaction between Interleukin 10 and Galectin-3 against Liver Ischemia-Reperfusion Injury Clin. Cancer Res., January 1, 2002; 8(1): 217 - 220. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
